The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
HER-2 gene amplification can be acquired as breast cancer progresses
Open accessAbstract
Amplification and overexpression of the HER-2 oncogene in breast cancer is felt to be stable over the course of disease and concordant between primary tumor and metastases. Therefore, patients with HER-2 -negative primary tumors rarely will receive anti-Her-2 antibody (trastuzumab, Herceptin) therapy. A very sensitive blood test was used to capture circulating tumor cells (CTCs) and evaluate their HER-2 gene status by fluorescence in situ hybridization. The HER-2 status of the primary tumor and corresponding CTCs in 31 patients showed 97% agreement, with no false positives. In 10 patients with HER-2 -positive tumors, the HER-2 /chromosome enumerator probe 17 ratio in each tumor was about twice that of the corresponding CTCs (mean 6.64 ± 2.72 vs. 2.8 ± 0.6). Hence, the ratio of the CTCs is a reliable surrogate marker for the expected high ratio in the primary tumor. Her-2 protein expression of 10 CTCs was sufficient to make a definitive diagnosis of the HER-2 gene status of the whole population of CTCs in 19 patients with recurrent breast cancer. Nine of 24 breast cancer patients whose primary tumor was HER-2 -negative each acquired HER-2 gene amplification in their CTCs during cancer progression, i.e., 37.5% (95% confidence interval of 18.8–59.4%). Four of the 9 patients were treated with Herceptin-containing therapy. One had a complete response and 2 had a partial response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Self-citationStudies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,816
Detection and characterization of carcinoma cells in the blood
Racila, E., Euhus, D., Weiss, A. J., Rao, C., McConnell, J., Terstappen, L. W. M. M., & Uhr, J. W. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.8.4589 · Cited by 712
Self-citationMomburg, F., Moldenhauer, G., Hämmerling, G. J., & Möller, P. (1987) · PubMed · Cited by 328
Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites
Gancberg, D., Di Leo, A., Cardoso, F., Rouas, G., Pedrocchi, M., Paesmans, M., Verhest, A., Bernard-Marty, C., Piccart, M. J., & Larsimont, D. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf252 · Cited by 309
Cytogenetic evidence that circulating epithelial cells in patients with carcinoma are malignant.
Fehm, T. N., Sagalowsky, A. I., Clifford, E., Beitsch, P. D., Saboorian, H. M., Euhus, D., Meng, S., Morrison, L. E., Tucker, T. F., Lane, N., et al. (2002) · PubMed · Cited by 307
Self-citationJackson, A. L., & Loeb, L. A. (1998) · Genetics · doi:10.1093/genetics/148.4.1483 · Cited by 253
Amplification of HER-2/neu and topoisomerase IIalpha in primary and metastatic breast cancer.
Tanner, M., Järvinen, P., & Isola, J. J. (2001) · PubMed · Cited by 215
First-line, single-agent Herceptin® (trastuzumab) in metastatic breast cancer
Vogel, C., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., et al. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(00)00405-6 · Cited by 183
Self-citation
Cited by
Riethdorf, S., Fritsche, H., Müller, V., Rau, T., Schindlbeck, C., Rack, B., Janni, W., Coith, C., Beck, K., Jänicke, F., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1695 · Cited by 1,338
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
Toy, W., Shen, Y., Won, H., Green, B., Sakr, R. A., Will, M., Li, Z., Gala, K., Fanning, S., King, T. A., et al. (2013) · Nature Genetics · doi:10.1038/ng.2822 · Cited by 1,248
Mechanisms of Endocrine Resistance in Breast Cancer
Osborne, C. K., & Schiff, R. (2011) · Annual Review of Medicine · doi:10.1146/annurev-med-070909-182917 · Cited by 1,166
Self-citationDetection, clinical relevance and specific biological properties of disseminating tumour cells
Pantel, K., Brakenhoff, R. H., & Brandt, B. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2375 · Cited by 1,118
Circulating tumor cells: approaches to isolation and characterization
Yu, M., Stott, S., Toner, M., Maheswaran, S., & Haber, D. A. (2011) · Journal of Cell Biology · doi:10.1083/jcb.201010021 · Cited by 1,089
Circulating Tumor Cells in Patients with Breast Cancer Dormancy
Meng, S., Tripathy, D., Frenkel, E. P., Shete, S., Naftalis, E. Z., Huth, J. F., Beitsch, P. D., Leitch, M., Hoover, S., Euhus, D., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1110 · Cited by 971
Self-citationCirculating tumor cells (CTC) detection: Clinical impact and future directions
Paterlini-Brechot, P., & Benali, N. L. (2007) · Cancer Letters · doi:10.1016/j.canlet.2006.12.014 · Cited by 947
Circulating tumour cells in cancer patients: challenges and perspectives
Pantel, K., & Alix-Panabières, C. (2010) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2010.07.001 · Cited by 815
Pantel, K., Alix-Panabières, C., & Riethdorf, S. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.44 · Cited by 643
Arpino, G., Wiechmann, L., Osborne, C. K., & Schiff, R. (2008) · Endocrine Reviews · doi:10.1210/er.2006-0045 · Cited by 549
Self-citationBiology of Progesterone Receptor Loss in Breast Cancer and Its Implications for Endocrine Therapy
Cui, X., Schiff, R., Arpino, G., Osborne, C. K., & Lee, A. V. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.004 · Cited by 514
Self-citationSpector, N. L., & Blackwell, K. L. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.1507 · Cited by 497
Riethdorf, S., Müller, V., Zhang, L., Rau, T., Loibl, S., Komor, M., Roller, M., Huober, J., Fehm, T., Schrader, I., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2042 · Cited by 490
Self-citationGutierrez, M. C., Detre, S., Johnston, S., Mohsin, S. K., Shou, J., Allred, D. C., Schiff, R., Osborne, C. K., & Dowsett, M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.172 · Cited by 489
Self-citationNCCN Task Force Report: Bone Health in Cancer Care
Gralow, J. R., Biermann, J. S., Farooki, A., Fornier, M. N., Gagel, R. F., Kumar, R., Litsas, G., McKay, R., Podoloff, D. A., Srinivas, S., et al. (2013) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2013.0215 · Cited by 412
Pierga, J.-Y., Bidard, F.-C., Mathiot, C., Brain, E., Delaloge, S., Giachetti, S., de Cremoux, P., Salmon, R., Vincent-Salomon, A., & Marty, M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0030 · Cited by 369
Challenges in circulating tumor cell detection by the CellSearch system
Andree, K. C., van Dalum, G., & Terstappen, L. W. M. M. (2016) · Molecular Oncology · doi:10.1016/j.molonc.2015.12.002 · Cited by 363
Self-citationIgnatiadis, M., Lee, M., & Jeffrey, S. S. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1190 · Cited by 355
Fehm, T., Müller, V., Aktas, B., Janni, W., Schneeweiss, A., Stickeler, E., Lattrich, C., Löhberg, C. R., Solomayer, E., Rack, B., et al. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1163-x · Cited by 353
Self-citationStrategies for the discovery and development of therapies for metastatic breast cancer
Eckhardt, B. L., Francis, P. A., Parker, B. S., & Anderson, R. L. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd2372 · Cited by 349
Prognostic versus predictive value of biomarkers in oncology
Oldenhuis, C. N. A. M., Oosting, S. F., Gietema, J. A., & de Vries, E. G. E. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.03.006 · Cited by 349
Seol, H., Lee, H. J., Choi, Y., Lee, H. E., Kim, Y. J., Kim, J. H., Kang, E., Kim, S.-W., & Park, S. Y. (2012) · Modern Pathology · doi:10.1038/modpathol.2012.36 · Cited by 330
Considerations in the development of circulating tumor cell technology for clinical use
Parkinson, D. R., Dracopoli, N., Petty, B. G., Compton, C., Cristofanilli, M., Deisseroth, A., Hayes, D. F., Kapke, G., Kumar, P., Lee, J. S., et al. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-138 · Cited by 323
Perik, P. J., Lub-De Hooge, M. N., Gietema, J. A., van der Graaf, W. T. A., de Korte, M. A., Jonkman, S., Kosterink, J. G. W., van Veldhuisen, D. J., Sleijfer, D. T., Jager, P. L., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.8448 · Cited by 310
Review: Biological relevance of disseminated tumor cells in cancer patients
Riethdorf, S., Wikman, H., & Pantel, K. (2008) · International Journal of Cancer · doi:10.1002/ijc.23825 · Cited by 309
Molecular Biomarker Analyses Using Circulating Tumor Cells
Punnoose, E. A., Atwal, S. K., Spoerke, J. M., Savage, H., Pandita, A., Yeh, R.-F., Pirzkall, A., Fine, B. M., Amler, L. C., Chen, D. S., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012517 · Cited by 294
Significance, detection and markers of disseminated breast cancer cells
Lacroix, M. (2006) · Endocrine-Related Cancer · doi:10.1677/erc-06-0001 · Cited by 293
Wang, Y.-C., Morrison, G., Gillihan, R., Guo, J., Ward, R. M., Fu, X., Botero, M. F., Healy, N. A., Hilsenbeck, S. G., Phillips, G. L., et al. (2011) · Breast Cancer Research · doi:10.1186/bcr3067 · Cited by 280
Self-citationTreatment of HER2-positive breast cancer
Figueroa-Magalhães, M. C., Jelovac, D., Connolly, R. M., & Wolff, A. C. (2014) · The Breast · doi:10.1016/j.breast.2013.11.011 · Cited by 273
Lianidou, E. S., & Markou, A. (2011) · Clinical Chemistry · doi:10.1373/clinchem.2011.165068 · Cited by 265
Circulating tumour cells: their utility in cancer management and predicting outcomes
Krebs, M. G., Hou, J.-M., Ward, T. H., Blackhall, F. H., & Dive, C. (2010) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834010378414 · Cited by 259
Wülfing, P., Borchard, J., Buerger, H., Heidl, S., Zänker, K. S., Kiesel, L., & Brandt, B. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2087 · Cited by 258
The Fluid Mechanics of Cancer and Its Therapy
Koumoutsakos, P., Pivkin, I., & Milde, F. (2013) · Annual Review of Fluid Mechanics · doi:10.1146/annurev-fluid-120710-101102 · Cited by 129
“Breast cancer tumors are also known to metastasize to the lungs, but circulating breast cancer cells have been detected in humans up to 22 years after successful treatment of the primary tumor (Meng et al. 2004).”
BackgroundDetection of HER2 amplification in circulating free DNA in patients with breast cancer
Page, K., Hava, N., Ward, B., Brown, J., Guttery, D. S., Ruangpratheep, C., Blighe, K., Sharma, A., Walker, R. A., Coombes, R. C., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.89 · Cited by 86
Metadata
- Authors
- Meng, S., Tripathy, D., Shete, S., Ashfaq, R., Haley, B., Perkins, S., Beitsch, P., Khan, A., Euhus, D., Osborne, C., Frenkel, E., Hoover, S., Leitch, M., Clifford, E., Vitetta, E., Morrison, L., Herlyn, D., Terstappen, L. W. M. M., Fleming, T., Fehm, T., Tucker, T., Lane, N., Wang, J., & Uhr, J.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2004-06-11
- Volume
- 101
- Issue
- 25
- Pages
- 9393-9398
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2125785648
- Cited by
- 508
- References
- 13
- FWCI
- 11.16
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.